Drugs

DGAP-News: Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Retrieved on: 
Monday, September 6, 2021
European Union, Sodium channel blockers, Drugs, Multilateral development banks, Financial services, Calcium channel blockers, Monoamine oxidase inhibitors, Economy of the European Union, InvestEU, Zambon, Safinamide, European Investment Bank

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
  • Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company's development programs in diseases of the central nervous system.
  • The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Retrieved on: 
Monday, September 6, 2021
Professional Services, Mental Health, Health, Finance, Pharmaceutical, Biotechnology, European Union, Multilateral development banks, Sodium channel blockers, Drugs, Financial services, Calcium channel blockers, Monoamine oxidase inhibitors, Economy of the European Union, InvestEU, Safinamide, European Investment Bank, Zambon

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
  • Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Companys development programs in diseases of the central nervous system.
  • The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

The Association of American Physicians and Surgeons (AAPS) Challenges the American Medical Association (AMA) on Efforts to Suppress Ivermectin Use in COVID

Retrieved on: 
Saturday, September 4, 2021
Health care, Drugs, Health, Symbols, Association of American Physicians and Surgeons, HIV/AIDS denialism, AAPS, Medical prescription, American Medical Association, Pharmacy, Ivermectin, Pharmacist

TUCSON, Ariz., Sept. 04, 2021 (GLOBE NEWSWIRE) -- In a letter to American Medical Association president Gerald Harmon , M.D., the Association of American Physicians and Surgeons (AAPS) raises questions concerning the AMAs startling and unprecedented position that American physicians should immediately stop prescribing, and pharmacists should stop honoring their prescriptions for ivermectin for COVID-19 patients.

Key Points: 
  • TUCSON, Ariz., Sept. 04, 2021 (GLOBE NEWSWIRE) -- In a letter to American Medical Association president Gerald Harmon , M.D., the Association of American Physicians and Surgeons (AAPS) raises questions concerning the AMAs startling and unprecedented position that American physicians should immediately stop prescribing, and pharmacists should stop honoring their prescriptions for ivermectin for COVID-19 patients.
  • AAPS points out that many physicians disagree with the AMA, writing around 88,000 ivermectin prescriptions per week.
  • Also the Chairman of the Tokyo Medical Association , Haruo Ozaki, recommended that all doctors in Japan immediately begin using ivermectin to treat COVID.
  • The Association of American Physicians and Surgeons has represented physicians in all specialties since 1943.

Let There Be Carnage: Sink Your Teeth Into New G FUEL "Black Ooze" And "Red Ooze" Energy Drinks

Retrieved on: 
Wednesday, August 4, 2021
Energy drinks, Psychoactive drugs, Drugs, Fictional characters, G Fuel, The Ooze, Caffeine, Venom Energy, Symbiote

In reality, there's only one way to get your tendrils on these two new G FUEL flavors: pre-order your limited-edition G FUEL Black Ooze and Red Ooze at gfuel.com through August 6th while symbiotes last.

Key Points: 
  • In reality, there's only one way to get your tendrils on these two new G FUEL flavors: pre-order your limited-edition G FUEL Black Ooze and Red Ooze at gfuel.com through August 6th while symbiotes last.
  • Each 16 oz G FUEL Black Ooze and Red Ooze Can has zero calories and contains 300 mg of caffeine.
  • Pre-order your limited-edition G FUEL Black Ooze and Red Ooze collector's boxes and tubs at gfuel.com/collections/venom before pre-orders close on August 6th.
  • As The Official Energy Drink of Esports, G FUEL provides gamers with a healthier, more performance-driven alternative to standard energy drink products.

Awakn Life Sciences Announces Its Second Location in the UK for "Awakn Clinics London," Providing Treatment to the Largest City in the UK

Retrieved on: 
Wednesday, August 4, 2021
Psychoactive drugs, Drugs, Health care, Clinics, Ketamine, Psychedelic therapy, Psychotherapy, Methadone clinic

Toronto, Ontario--(Newsfile Corp. - August 4, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the signing of its 10-year lease to open Awakn Clinics London, a psychedelic-focused therapy center to treat Addiction and other mental health conditions.

Key Points: 
  • Awakn Clinics London will join Awakn Clinics Bristol as the only clinics in the world providing evidence backed Ketamine-Assisted Psychotherapy for Alcohol Use Disorder.
  • Awakn Clinics London, a 5,000 square-foot, 8 treatment room clinic, will deliver psychedelic-assisted psychotherapy treatments, such as ketamine-assisted therapies.
  • Awakn Clinics London will be owned and operated by Awakn and will be led by on-site psychiatrists.
  • Awakn Clinics London will be the second of three Awakn clinics to open this year in the UK.

Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines

Retrieved on: 
Wednesday, August 4, 2021
Cannabinoids, Drugs, Chemical compounds, Branches of biology, Cannabidiol, Endocannabinoid system, In vitro, CBD, Pharmacology

SOLANA BEACH, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced the publication of study results in Medical Cannabis and Cannabinoids, a peer-reviewed journal. The study and related article, entitled “The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines,” compared the in vitro effects of purified natural and synthetic forms of Cannabidiol (CBD) to establish any pharmacological differences in human cell lines. The study found no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD.

Key Points: 
  • The study and related article, entitled The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines , compared the in vitro effects of purified natural and synthetic forms of Cannabidiol (CBD) to establish any pharmacological differences in human cell lines.
  • The study found no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD.
  • The company-sponsored study was led by Prof. Saoirse OSullivan, scientific advisor to Artelo Biosciences and former Professor of Pharmacology at the University of Nottingham, UK.
  • Artelo Biosciences, Inc.is a clinical stage biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that target lipid signaling pathways, including the endocannabinoid system.

BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine

Retrieved on: 
Wednesday, August 4, 2021
Migraine, Triptans, Drugs, Migraine treatment, Prevention of migraines

RALEIGH, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced today that it entered into an agreement on August 3, 2021 with Dr. Reddy’s Laboratories Limited to acquire the U.S. and Canadian rights to ELYXYB (celecoxib oral solution), the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.

Key Points: 
  • In pivotal studies, ELYXYB demonstrated a rapid onset of action which is critically important to patients suffering from acute migraine attacks.
  • The results from pivotal studies established the efficacy of ELYXYB in the treatment of acute migraine.
  • ELYXYBs unit-dose oral solution makes it convenient for patients to take it immediately upon emergence of acute migraine attacks.
  • We believe that this profile, coupled with the ready-to-use oral solution, make ELYXYB an attractive option for the acute treatment of migraine in adults.

Day One Biopharmaceuticals to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Health sciences, Biotechnology, Drugs, Targeted therapy, Treatment of cancer, Oncology, Cancer, Biopharmaceutical, Cancer research

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers.

Key Points: 
  • Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers.
  • Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution.
  • We aim to re-envision cancer drug development and redefine whats possible for all people living with cancerregardless of agestarting from Day One.
  • Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments.

Dr. Reddy’s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL

Retrieved on: 
Wednesday, August 4, 2021
Health, Pharmaceutical, Nonsteroidal anti-inflammatory drugs, Drugs, Hepatotoxins, Organ systems, Clinical medicine, COX-2 inhibitors, Migraine, Stroke, Celecoxib, Myocardial infarction, Anti-inflammatory, Rofecoxib

Under the terms of agreement, Dr.Reddys will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing.

Key Points: 
  • Under the terms of agreement, Dr.Reddys will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing.
  • ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults.
  • ELYXYB is an oral solution dosage form which makes it convenient for patients to take it immediately upon emergence of migraine attacks.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

US Cannabis Council Elects Akerna CEO, Jessica Billingsley, as Board Chair

Retrieved on: 
Wednesday, August 4, 2021
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Psychoactive drugs, Drugs

Billingsley was unanimously elected as chair due to her leadership experience in the cannabis industry.

Key Points: 
  • Billingsley was unanimously elected as chair due to her leadership experience in the cannabis industry.
  • To do so, USCC works hand-in-hand with Congressional leaders in Washington, DC and throughout the country to advance cannabis reform.
  • Billingsley was unanimously elected as chair due to her leadership experience in the cannabis industry.
  • "Her extensive background working in the cannabis industry and with government will greatly assist USCC in reforming cannabis policy and advancing an equitable, well-regulated cannabis industry in all fifty states.